Publication date: Apr 10, 2019
This post was originally published on this site The effectiveness of Mayzent (siponimod) in both the brain and the body make it an oral therapy tailored for people with early secondary progressive multiple sclerosis (SPMS), according to Dan Bar-Zohar, MD, top executive with Novartis, the treatment’s developer. That’s because Mayzent enters the brain -avidly,” Fox and Bar-Zohar said, where two cell types implicated in the accumulation of injury contain high levels of S1P5: astrocytes, involved in the formation of the blood-brain barrier, and oligodendrocytes, the cells that form the myelin sheet around nerve fibers. This work -suggests that Mayzent has beneficial effects through these cells, through .. . astrocyctes and through oligodendrocytes in order to ameliorate clinical symptoms of progressive disease,” Bar-Zohar said. Likely future trials Novartis is planning to test the therapy in pediatric patients after it concludes ongoing discussions with the European Medicines Agency regarding Mayzent’s approval in Europe. The company is currently conducting a Phase 3 study in the U. S., named EXCHANGE (NCT03623243), assessomg the safety and tolerability of switching patients from other disease-modifying therapies to Mayzent. A future trial, still in planning phases, aims to look at the benefits of identifying SPMS early and starting treatment with Mayzent compared to keeping patients on their current therapy. The post Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says appeared first on Multiple Sclerosis News Today.
|disease||MESH||secondary progressive multiple sclerosis|
- Mayzent ‘Will Change Lives’ of MS Patients Transitioning to SPMS, Novartis Says
- FDA Approves Oral Drug Mayzent To Treat Multiple Sclerosis, Novartis Expected To Get $1.7 Billion In Revenue By 2026
- Novartis gets FDA nod for multiple sclerosis drug Mayzent
- SPMS Treatment With Mayzent Could Be Cost-effective, ICER Report Says
- Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi-Center Phase IIIb Study
- Secondary progressive multiple sclerosis and the gut-brain axis.
- #AAN2019 – Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows